Recovery
TB-500
Also called Thymosin Beta-4 fragment
per administration
Only animal or lab studies exist — no human study has set an amount.
Quick start
TB-500 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 2–5 mg per administration
- How often
- 2x per week
- Where
- Commonly subcutaneous Sites and rotation
- Timing
- Commonly run as a twice-weekly loading period, then less often.
- What people report
- Reports describe a gradual timeline over weeks rather than days.
- Time to steady level
- ~12.5 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- 4–6 loading weeks
- Break between
- 2–4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C212H350N56O78S
- Mol. weight
- 4,963.4 Da
- CAS
- 77591-33-4
- PubChem CID
- 45382195
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for TB-500 describe 2–5 mg per administration. Descriptive only, not a recommendation.
Estimates for the parent protein; fragment data is thin.
Human pharmacokinetics for the fragment are thin and no trial fixes an injected schedule; circulating amounts are community-derived, so no schedule table is shown.
What it can be combined with
How TB-500 is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
Modelled level — 2x per week
1× is the peak after a single dose.
- Steady-state peak
- 1.65× single dose
- Time to steady state
- 12.5days
- Administrations
- 2/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Thymosin β4 preclinical repair literatureThe fragment's human pharmacokinetics are thin; figures derive from the parent protein and community-reported use.